# Association Between Microbiome and the Efficacy and Safety of PD-1/PD-L1 Blockade in Resectable NSCLC

> **NCT06613308** · — · NOT_YET_RECRUITING · sponsor: **Capital Medical University** · enrollment: 20 (estimated)

## Conditions studied

- Lung Cancer (NSCLC)

## Interventions

- **DRUG:** Neoadjuvant immunotherapy combined with chemotherapy
- **DRUG:** Neoadjuvant chemotherapy

## Key facts

- **NCT ID:** NCT06613308
- **Lead sponsor:** Capital Medical University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-09-25
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2024-09-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06613308

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06613308, "Association Between Microbiome and the Efficacy and Safety of PD-1/PD-L1 Blockade in Resectable NSCLC". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06613308. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*